Neo Ivy Capital Management’s Neurocrine Biosciences NBIX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q4 | $320K | Buy |
2,682
+2,502
| +1,390% | +$299K | 0.22% | 191 |
|
|
2022
Q3 | $19K | Buy |
+180
| New | +$19K | 0.05% | 300 |
|
|
2022
Q2 | – | Sell |
-2,216
| Closed | -$208K | – | 542 |
|
|
2022
Q1 | $208K | Buy |
2,216
+232
| +12% | +$21.8K | 0.19% | 190 |
|
|
2021
Q4 | $169K | Buy |
+1,984
| New | +$169K | 0.24% | 155 |
|
|
2021
Q3 | – | Sell |
-143
| Closed | -$14K | – | 574 |
|
|
2021
Q2 | $14K | Buy |
+143
| New | +$14K | 0.01% | 382 |
|
|
2020
Q4 | – | Sell |
-3,884
| Closed | -$373K | – | 527 |
|
|
2020
Q3 | $373K | Buy |
+3,884
| New | +$373K | 0.38% | 90 |
|
|
2020
Q2 | – | Sell |
-1,397
| Closed | -$121K | – | 550 |
|
|
2020
Q1 | $121K | Sell |
1,397
-2,146
| -61% | -$186K | 0.2% | 195 |
|
|
2019
Q4 | $381K | Buy |
+3,543
| New | +$381K | 0.44% | 95 |
|
|
2019
Q1 | – | Sell |
-6,499
| Closed | -$464K | – | 366 |
|
|
2018
Q4 | $464K | Buy |
+6,499
| New | +$464K | 0.37% | 124 |
|